6-methylimidazo[1,2-a]pyridine-5-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 6-methylimidazo[1,2-a]pyridine-5-carboxylic acid
• 英文别名: 6-Methylimidazo[1,2-a]pyridine-5-carboxylic acid
• 化学式: C₉H₈N₂O₂
• 分子量: 176.175
• InChiKey: VFAHKVWLINQGPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-氨基-3-溴吡啶甲酸甲酯 在 四(三苯基膦)钯 、 水 、 lithium chloride 、 sodium hydroxide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 6-methylimidazo[1,2-a]pyridine-5-carboxylic acid
  参考文献：
  名称：

  SUBSTITUTED 7-AZABICYCLES AND THEIR USE AS OREXIN RECEPTOR MODULATORS

  摘要：

  本发明涉及式I的化合物：其中环A为苯基、萘基、吡啶基、喹啉基、异喹啉基、咪唑吡啉基、呋喃基、噻唑基、异噁唑基、吡唑基、咪唑噻唑基、苯并咪唑基或吲哚基；R1为H、烷基、烷氧基、羟基烷基、OH、卤素、苯基、三唑基、噁唑基、异噁唑基、吡啶基、嘧啶基、吡嗪基、吡啶并嗪基、哌嗪基、吡唑基、噁二唑基、吡咯烷基、噻吩基、吗啉基或二烷氨基；R2为H、烷基、烷氧基、羟基烷基或卤素；Z为NH、N-烷基或O；R5为吡啶基、嘧啶基、吡嗪基、吡啶并嗪基、喹唑啉基、喹喹啉基、吡唑基、苯并噁唑基、咪唑吡嗪基、三唑咪唑基，可选地取代一个或两个独立选择自烷基、烷氧基或卤素的基团；n为0或1，还描述了制备式I化合物的方法。本发明还涉及包含式I化合物的药物组合物。本发明还涉及使用该化合物的方法。

  公开号：

  US20160046640A1

文献信息

• Substituted 7-azabicyles and their use as orexin receptor modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US09062078B2

  公开（公告）日：2015-06-23

  The present invention is directed to compounds of Formula I: wherein ring A is phenyl, naphthalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyl, thiazolyl, isoxazolyl, pyrazolyl, imidazothiazolyl, benzimidazolyl, or indazolyl; R1 is H, alkyl, alkoxy, hydroxyalkylene, OH, halo, phenyl, triazolyl, oxazolyl, isoxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperazinyl, pyrazolyl, oxadiazolyl, pyrrolidinyl, thiophenyl, morpholinyl, or dialkylamino; R2 is H, alkyl, alkoxy, hydroxyalkylene, or halo; Z is NH, N-alkyl, or O; R5 is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinazolinyl, quinoxalinyl, pyrazolyl, benzoxazolyl, imidazopyrazinyl, triazolopyrazinyl, optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, alkoxy, or halo; and n is 0 or 1. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.

  本发明涉及式I的化合物：其中环A是苯基，萘基，吡啶基，喹啉基，异喹啉基，咪唑吡啶基，呋喃基，噻唑基，异恶唑基，吡唑基，咪唑噻唑基，苯并咪唑基或吲唑基; R1是H，烷基，烷氧基，羟基烷基，OH，卤素，苯基，三唑基，噁唑基，异噁唑基，吡啶基，嘧啶基，吡嗪基，吡啶并嗪基，哌嗪基，吡唑基，噁二唑基，吡咯烷基，噻吩基，吗啉基或二烷基氨基; R2是H，烷基，烷氧基，羟基烷基或卤素; Z是NH，N-烷基或O; R5是吡啶基，嘧啶基，吡嗪基，吡啶并嗪基，喹唑啉基，喹喔啉基，吡唑基，苯并噁唑基，咪唑吡嗪基，三唑基咪唑基，可选地带有一个或两个烷基，烷氧基或卤素基团; n为0或1。还描述了制备式I化合物的方法。本发明还涉及包含式I化合物的制药组合物。使用本发明中的化合物的方法也属于本发明的范围。
• US20140275065A1
  申请人：——

  公开号：——

  公开（公告）日：——
• Substituted 7-Azabicycles And Their Use As Orexin Receptor Modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US20160376280A1

  公开（公告）日：2016-12-29

  The present invention is directed to compounds of Formula I: wherein A is phenyl, naphthalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyl, thiazolyl, isoxazolyl, pyrazolyl, imidazothiazolyl, benzimidazolyl, or indazolyl; R 1 is H, alkyl, alkoxy, hydroxyalkylene, OH, halo, phenyl, triazolyl, oxazolyl, isoxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperazinyl, pyrazolyl, oxadiazolyl, pyrrolidinyl, thiophenyl, morpholinyl, or dialkylamino; R 2 is H, alkyl, alkoxy, hydroxyalkylene, or halo; Z is NH, N-alkyl, or O; R 5 is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinazolinyl, quinoxalinyl, pyrazolyl, benzoxazolyl, imidazopyrazinyl, or triazolopyrazinyl, optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, alkoxy, or halo; and n is 0 or 1. Methods of making the compounds of Formula I are also described. The invention also relates to pharmaceutical compositions comprising compounds of Formula I. Methods of using the compounds of the invention are also within the scope of the invention.
• US9062078B2
  申请人：——

  公开号：US9062078B2

  公开（公告）日：2015-06-23
• US9475819B2
  申请人：——

  公开号：US9475819B2

  公开（公告）日：2016-10-25